<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="scale and is a potential candidate therapy for pandemic coronavirus" exact="disease" post="2019 (COVID-19). Azithromycin was widely used to treat severe"/>
 <result pre="available in any coronavirus infections. Other ongoing trials are exploring" exact="short" post="courses of azithromycin either in early disease, within the"/>
 <result pre="when azithromycinâ€™s antiviral properties may be important, or late in" exact="disease" post="when anti-bacterial properties may reduce the risk of secondary"/>
 <result pre="in disease when anti-bacterial properties may reduce the risk of" exact="secondary" post="bacterial infection. However, the moleculeâ€™s anti-inflammatory properties, including suppression"/>
 <result pre="disease when anti-bacterial properties may reduce the risk of secondary" exact="bacterial infection." post="However, the moleculeâ€™s anti-inflammatory properties, including suppression of pulmonary"/>
 <result pre="bacterial infection. However, the moleculeâ€™s anti-inflammatory properties, including suppression of" exact="pulmonary" post="macrophage-derived pro-inflammatory cytokines such as interleukins-1Î², -6, -8, and"/>
 <result pre="presentation. We will enrol adults, â‰¥â€‰18â€‰years of age assessed in" exact="acute" post="hospitals in the UK with clinical diagnosis of COVID-19"/>
 <result pre="acute hospitals in the UK with clinical diagnosis of COVID-19" exact="infection" post="where management on an ambulatory care pathway is deemed"/>
 <result pre="14â€‰days with telephone follow-up at days 14 and 28. The" exact="primary" post="objective is to compare the proportion with either death"/>
 <result pre="objective is to compare the proportion with either death or" exact="respiratory" post="failure requiring invasive or non-invasive mechanical ventilation over 28â€‰days"/>
 <result pre="requiring invasive or non-invasive mechanical ventilation over 28â€‰days from randomisation." exact="Secondary" post="objectives include mortality/respiratory failure in those with a PCR-confirmed"/>
 <result pre="2020. Keywords COVID-19 Coronavirus SAR-CoV-2 Azithromycin Macrolide Randomised controlled trial" exact="Respiratory" post="failure Mortality Trial Funding http://dx.doi.org/10.13039/501100013373NIHR Oxford Biomedical Research Centre"/>
 <result pre="of MERS-CoV [1], and azithromycin has been tried in COVID-19" exact="infection" post="[2] although RCT data for any coronavirus disease are"/>
 <result pre="in COVID-19 infection [2] although RCT data for any coronavirus" exact="disease" post="are lacking [3]. Antiviral properties Azithromycin has well-documented, broad"/>
 <result pre="vitro. Numerous studies have shown it to be effective against" exact="respiratory" post="viruses, including the picornavirus human rhinovirus (RV), where it"/>
 <result pre="including the picornavirus human rhinovirus (RV), where it enhances viral-induced" exact="type I" post="and type III interferons and interferon-stimulated gene (ISG) expression"/>
 <result pre="human rhinovirus (RV), where it enhances viral-induced type I and" exact="type III" post="interferons and interferon-stimulated gene (ISG) expression and reduced RV"/>
 <result pre="release [4â€&quot;6]. Macrolides reduce RV replication in vitro by enhancing" exact="type I" post="and III IFN and induce the antiviral ISGs viperin"/>
 <result pre="effects, as viruses trigger up to 80% of exacerbations in" exact="asthma" post="[8, 9]. AZM has antiviral activity against SARS-CoV-2 in"/>
 <result pre="antiviral activity against SARS-CoV-2 in vitro, being shown to reduce" exact="viral" post="replication in combination with hydroxychloroquine [10]. Azithromycin was also"/>
 <result pre="with hydroxychloroquine [10]. Azithromycin was also associated with a reduced" exact="viral" post="load of non-SARS-CoV-2 alpha- and betacoronaviruses in children receiving"/>
 <result pre="in a drug screen of 2177 compounds and markedly reduce" exact="viral" post="proliferation and virus-induced cytopathic effects [13]. In Zika, AZM"/>
 <result pre="proliferation and virus-induced cytopathic effects [13]. In Zika, AZM upregulates" exact="type 1" post="and type III interferon responses and the viral pathogen"/>
 <result pre="cytopathic effects [13]. In Zika, AZM upregulates type 1 and" exact="type III" post="interferon responses and the viral pathogen recognition receptors MDA5"/>
 <result pre="upregulates type 1 and type III interferon responses and the" exact="viral" post="pathogen recognition receptors MDA5 and RIG-I and increases the"/>
 <result pre="antiviralâ€&quot;will be more important in the treatment of severe COVID-19" exact="disease" post="in secondary care. Antivirals are likely to have limited"/>
 <result pre="more important in the treatment of severe COVID-19 disease in" exact="secondary" post="care. Antivirals are likely to have limited efficacy in"/>
 <result pre="COVID-19 disease in secondary care. Antivirals are likely to have" exact="limited" post="efficacy in severe disease as they are administered late"/>
 <result pre="care. Antivirals are likely to have limited efficacy in severe" exact="disease" post="as they are administered late in the disease, after"/>
 <result pre="influenza A, most COVID-19-related deaths occur due to sudden, late" exact="respiratory" post="decompensation, peaking at day 14 after the onset of"/>
 <result pre="14 after the onset of symptoms [23]. By this time," exact="viral" post="loads are low, and it is during the adaptive"/>
 <result pre="by lymphocytes [26]. This points to a failure not of" exact="viral" post="control, but of the ability to halt an over-exuberant"/>
 <result pre="signalling cascades, which are characteristically steroid-resistant [22] and associated with" exact="pulmonary" post="inflammation and extensive lung damage in SARS patients [27]"/>
 <result pre="G-CSF and GM-CSF [29â€&quot;32] and other components of the IL-1Î²/IL-6-induced" exact="acute" post="phase response such as serum amyloid protein A [30]."/>
 <result pre="asthma, COPD, CF and obliterative bronchiolitis, post lung transplant obliterative" exact="bronchiolitis" post="and diffuse pan bronchiolitis (DPB): a disease characterised by"/>
 <result pre="CF and obliterative bronchiolitis, post lung transplant obliterative bronchiolitis and" exact="diffuse" post="pan bronchiolitis (DPB): a disease characterised by alveolar accumulation"/>
 <result pre="obliterative bronchiolitis, post lung transplant obliterative bronchiolitis and diffuse pan" exact="bronchiolitis" post="(DPB): a disease characterised by alveolar accumulation of foamy"/>
 <result pre="lung transplant obliterative bronchiolitis and diffuse pan bronchiolitis (DPB): a" exact="disease" post="characterised by alveolar accumulation of foamy macrophages [29, 33]."/>
 <result pre="upregulation of CD206, the macrophage mannose receptor [43]. AZM attenuates" exact="type 1" post="response and shifts macrophage polarisation to a more immunosuppressive,"/>
 <result pre="is active against a range of gram-positive, gram-negative, anaerobic and" exact="atypical" post="infections may reduce secondary infection which were found in"/>
 <result pre="active against a range of gram-positive, gram-negative, anaerobic and atypical" exact="infections" post="may reduce secondary infection which were found in 16%"/>
 <result pre="range of gram-positive, gram-negative, anaerobic and atypical infections may reduce" exact="secondary" post="infection which were found in 16% of COVID-19 deaths"/>
 <result pre="of gram-positive, gram-negative, anaerobic and atypical infections may reduce secondary" exact="infection" post="which were found in 16% of COVID-19 deaths [23]."/>
 <result pre="is associated with diarrhoea. Whilst there have been concerns about" exact="cardiovascular" post="risk, huge epidemiological studies suggest these are very small"/>
 <result pre="effect when corrected for confounding. It is contraindicated in known" exact="hypersensitivity" post="to the drug. It can be used in pregnancy."/>
 <result pre="similar to the dose recommended in UK for treatment of" exact="Lyme disease" post="[47]. This dose is selected to be known to"/>
 <result pre="to the dose recommended in UK for treatment of Lyme" exact="disease" post="[47]. This dose is selected to be known to"/>
 <result pre="cover the period during which progression from moderate to severe" exact="disease" post="may occur and during which anti-inflammatory effects may be"/>
 <result pre="determine whether azithromycin is effective in preventing progression to severe" exact="respiratory" post="failure requiring ventilatory support or death in adult patients"/>
 <result pre="to severe respiratory failure requiring ventilatory support or death in" exact="adult" post="patients with clinically diagnosed COVID-19 infection being assessed in"/>
 <result pre="support or death in adult patients with clinically diagnosed COVID-19" exact="infection" post="being assessed in secondary care but initially managed on"/>
 <result pre="adult patients with clinically diagnosed COVID-19 infection being assessed in" exact="secondary" post="care but initially managed on an ambulatory care pathway."/>
 <result pre="14â€‰days is effective in preventing and/or reducing the severity of" exact="lower" post="respiratory illness of COVID-19 disease at 28â€‰days. Primary objective"/>
 <result pre="is effective in preventing and/or reducing the severity of lower" exact="respiratory" post="illness of COVID-19 disease at 28â€‰days. Primary objective The"/>
 <result pre="and/or reducing the severity of lower respiratory illness of COVID-19" exact="disease" post="at 28â€‰days. Primary objective The primary objective is to"/>
 <result pre="severity of lower respiratory illness of COVID-19 disease at 28â€‰days." exact="Primary" post="objective The primary objective is to compare the effect"/>
 <result pre="respiratory illness of COVID-19 disease at 28â€‰days. Primary objective The" exact="primary" post="objective is to compare the effect of azithromycin in"/>
 <result pre="reducing the proportion with either death or hospital admission with" exact="respiratory" post="failure requiring invasive or non-invasive mechanical ventilation over 28â€‰days"/>
 <result pre="requiring invasive or non-invasive mechanical ventilation over 28â€‰days from randomisation." exact="Secondary" post="objectives The secondary objectives are to compare the effect"/>
 <result pre="non-invasive mechanical ventilation over 28â€‰days from randomisation. Secondary objectives The" exact="secondary" post="objectives are to compare the effect of azithromycin in"/>
 <result pre="reducing the proportion with either death or hospital admission with" exact="respiratory" post="failure requiring invasive or non-invasive mechanical ventilatory support over"/>
 <result pre="to pneumonia, to compare differences in proportion progressing to severe" exact="pneumonia" post="and to compare differences in peak severity of illness."/>
 <result pre="of indications including treatment or prevention of a range of" exact="bacterial infections" post="of the respiratory tract, ear, skin and soft tissue,"/>
 <result pre="indications including treatment or prevention of a range of bacterial" exact="infections" post="of the respiratory tract, ear, skin and soft tissue,"/>
 <result pre="or prevention of a range of bacterial infections of the" exact="respiratory" post="tract, ear, skin and soft tissue, genital tract, and"/>
 <result pre="aspects. Firstly, they are studying different time points in the" exact="disease" post="course: for instance, the PRINCIPLE trial is investigating people"/>
 <result pre="the first 7â€‰days of symptoms, the RECOVERY trial in late" exact="disease" post="after hospitalisation with severe clinical features. Secondly, they are"/>
 <result pre="Secondly, they are recruiting in different settings, the former in" exact="primary" post="care, the latter in secondary care. Thirdly, they are"/>
 <result pre="different settings, the former in primary care, the latter in" exact="secondary" post="care. Thirdly, they are using different dose regimens, the"/>
 <result pre="early disease, PRINCIPLE will explore antiviral effects, in very late" exact="disease" post="RECOVERY is likely to expose anti-bacterial activities against secondary"/>
 <result pre="late disease RECOVERY is likely to expose anti-bacterial activities against" exact="secondary" post="infection, whilst ATOMIC2 is intermediate and predominantly assessing AZMâ€™s"/>
 <result pre="to expose anti-bacterial activities against secondary infection, whilst ATOMIC2 is" exact="intermediate" post="and predominantly assessing AZMâ€™s anti-inflammatory effects. ATOMIC2 is positioned"/>
 <result pre="and predominantly assessing AZMâ€™s anti-inflammatory effects. ATOMIC2 is positioned between" exact="primary" post="and secondary care populations with several unique features. Selection"/>
 <result pre="assessing AZMâ€™s anti-inflammatory effects. ATOMIC2 is positioned between primary and" exact="secondary" post="care populations with several unique features. Selection of a"/>
 <result pre="unique features. Selection of a population who have presented to" exact="secondary" post="care will focus recruitment on those with significant early"/>
 <result pre="2â€‰weeks, and yet, we believe, not too late in the" exact="disease" post="process for suppression of pulmonary macrophage-derived inflammatory cytokines to"/>
 <result pre="not too late in the disease process for suppression of" exact="pulmonary" post="macrophage-derived inflammatory cytokines to have a potentially clinically meaningful"/>
 <result pre="adverse event of concern in this trial would be potential" exact="cardiovascular" post="toxicity. Although macrolides have a class warning for potential"/>
 <result pre="large study of Medicaid prescriptions reported an additional risk of" exact="cardiovascular" post="death of 47 extra deaths/million compared with amoxicillin (relative"/>
 <result pre="47 extra deaths/million compared with amoxicillin (relative risk (RR) for" exact="cardiovascular" post="death 2.49 [55], and a meta-analysis of 20 million"/>
 <result pre="20 million patients suggested a RR for cardiac death or" exact="ventricular tachycardia" post="of 2.42 [56]. However, these effects are very small"/>
 <result pre="baseline and at subsequent admission for both blood and nasal" exact="epithelial" post="samples. Using proteomics, direct ex vivo functional T cell"/>
 <result pre="response and also insight into the immune consequences of SARS-CoV-2" exact="infection" post="on the peripheral blood and airway epithelial cell transcriptome."/>
 <result pre="insight into the immune consequences of SARS-CoV-2 infection on the" exact="peripheral" post="blood and airway epithelial cell transcriptome. Such insights into"/>
 <result pre="consequences of SARS-CoV-2 infection on the peripheral blood and airway" exact="epithelial" post="cell transcriptome. Such insights into the pathogenic mechanisms of"/>
 <result pre="4. LINK Additional file 5. Abbreviations AZM Azithromycin BTS British" exact="Thoracic" post="Society COVID-19 Coronavirus disease 2019 CURB-65 Confusion, urea &amp;gt;â€‰7.0"/>
 <result pre="5. Abbreviations AZM Azithromycin BTS British Thoracic Society COVID-19 Coronavirus" exact="disease" post="2019 CURB-65 Confusion, urea &amp;gt;â€‰7.0 mmol/L, respiratory rate â‰¥â€‰30"/>
 <result pre="Society COVID-19 Coronavirus disease 2019 CURB-65 Confusion, urea &amp;gt;â€‰7.0 mmol/L," exact="respiratory" post="rate â‰¥â€‰30 breaths/min, blood pressure EDTA Ethylenediaminetetraacetic acid ePR"/>
 <result pre="blood pressure EDTA Ethylenediaminetetraacetic acid ePR Electronic patient record IMV" exact="Invasive" post="mechanical ventilation MERS Middle East respiratory syndrome NHS National"/>
 <result pre="Electronic patient record IMV Invasive mechanical ventilation MERS Middle East" exact="respiratory" post="syndrome NHS National Health Service (UK) PCR Polymerase chain"/>
 <result pre="patient record IMV Invasive mechanical ventilation MERS Middle East respiratory" exact="syndrome" post="NHS National Health Service (UK) PCR Polymerase chain reaction"/>
 <result pre="PCR Polymerase chain reaction RNA Ribonucleic acid RV Rhinovirus SARS" exact="Severe" post="acute respiratory syndrome SPIRIT Standard Protocol Items: Recommendations for"/>
 <result pre="Polymerase chain reaction RNA Ribonucleic acid RV Rhinovirus SARS Severe" exact="acute" post="respiratory syndrome SPIRIT Standard Protocol Items: Recommendations for Interventional"/>
 <result pre="chain reaction RNA Ribonucleic acid RV Rhinovirus SARS Severe acute" exact="respiratory" post="syndrome SPIRIT Standard Protocol Items: Recommendations for Interventional Trials"/>
 <result pre="reaction RNA Ribonucleic acid RV Rhinovirus SARS Severe acute respiratory" exact="syndrome" post="SPIRIT Standard Protocol Items: Recommendations for Interventional Trials SSRI"/>
 <result pre="syndrome SPIRIT Standard Protocol Items: Recommendations for Interventional Trials SSRI" exact="Selective" post="serotonin reuptake inhibitor SST Serum separator tube QTc Corrected"/>
 <result pre="References 1.ArabiYMDeebAMAl-HameedFMandourahYAlmekhlafiGASindiAAet al.Macrolides in critically ill patients with Middle East" exact="Respiratory" post="SyndromeInt J Infect Dis20198118419030690213 2.GautretPLagierJParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and azithromycin as"/>
 <result pre="COVID-19. medRxiv. 2020. 10.1101/2020.03.18.20038190. 4.GielenVJohnstonSLEdwardsMRAzithromycin induces anti-viral responses in bronchial" exact="epithelial" post="cellsEur Respir J201036364665420150207 5.SchoglerAKopfBSEdwardsMRJohnstonSLCasaultaCKieningerEet al.Novel antiviral properties of azithromycin"/>
 <result pre="cellsEur Respir J201036364665420150207 5.SchoglerAKopfBSEdwardsMRJohnstonSLCasaultaCKieningerEet al.Novel antiviral properties of azithromycin in" exact="cystic fibrosis" post="airway epithelial cellsEur Respir J201545242843925359346 6.PorterJDWatsonJRobertsLRGillSKGrovesHDhariwalJet al.Identification of novel"/>
 <result pre="5.SchoglerAKopfBSEdwardsMRJohnstonSLCasaultaCKieningerEet al.Novel antiviral properties of azithromycin in cystic fibrosis airway" exact="epithelial" post="cellsEur Respir J201545242843925359346 6.PorterJDWatsonJRobertsLRGillSKGrovesHDhariwalJet al.Identification of novel macrolides with"/>
 <result pre="J201545242843925359346 6.PorterJDWatsonJRobertsLRGillSKGrovesHDhariwalJet al.Identification of novel macrolides with antibacterial, anti-inflammatory and" exact="type I" post="and III IFN-augmenting activity in airway epitheliumJ Antimicrob Chemother201671102767278127494903"/>
 <result pre="in airway epitheliumJ Antimicrob Chemother201671102767278127494903 7.GibsonPGYangIAUphamJWReynoldsPNHodgeSJamesALet al.Effect of azithromycin on" exact="asthma" post="exacerbations and quality of life in adults with persistent"/>
 <result pre="asthma exacerbations and quality of life in adults with persistent" exact="uncontrolled" post="asthma (AMAZES): a randomised, double-blind, placebo-controlled trialLancet.20173901009565966828687413 8.JohnstonSLPattemorePKSandersonGSmithSLampeFJosephsLet al.Community"/>
 <result pre="exacerbations and quality of life in adults with persistent uncontrolled" exact="asthma" post="(AMAZES): a randomised, double-blind, placebo-controlled trialLancet.20173901009565966828687413 8.JohnstonSLPattemorePKSandersonGSmithSLampeFJosephsLet al.Community study"/>
 <result pre="randomised, double-blind, placebo-controlled trialLancet.20173901009565966828687413 8.JohnstonSLPattemorePKSandersonGSmithSLampeFJosephsLet al.Community study of role of" exact="viral" post="infections in exacerbations of asthma in 9-11 year old"/>
 <result pre="double-blind, placebo-controlled trialLancet.20173901009565966828687413 8.JohnstonSLPattemorePKSandersonGSmithSLampeFJosephsLet al.Community study of role of viral" exact="infections" post="in exacerbations of asthma in 9-11 year old childrenBMJ.19953106989122512297767192"/>
 <result pre="al.Community study of role of viral infections in exacerbations of" exact="asthma" post="in 9-11 year old childrenBMJ.19953106989122512297767192 9.JohnstonSLPattemorePKSandersonGSmithSCampbellMJJosephsLKet al.The relationship between"/>
 <result pre="asthma in 9-11 year old childrenBMJ.19953106989122512297767192 9.JohnstonSLPattemorePKSandersonGSmithSCampbellMJJosephsLKet al.The relationship between" exact="upper" post="respiratory infections and hospital admissions for asthma: a time-trend"/>
 <result pre="in 9-11 year old childrenBMJ.19953106989122512297767192 9.JohnstonSLPattemorePKSandersonGSmithSCampbellMJJosephsLKet al.The relationship between upper" exact="respiratory" post="infections and hospital admissions for asthma: a time-trend analysisAm"/>
 <result pre="9-11 year old childrenBMJ.19953106989122512297767192 9.JohnstonSLPattemorePKSandersonGSmithSCampbellMJJosephsLKet al.The relationship between upper respiratory" exact="infections" post="and hospital admissions for asthma: a time-trend analysisAm J"/>
 <result pre="13.RetallackHDi LulloEAriasCKnoppKALaurieMTSandoval-EspinosaCet al.Zika virus cell tropism in the developing human" exact="brain" post="and inhibition by azithromycinProc Natl Acad Sci U S"/>
 <result pre="Parvatiyar K, Quanquin N, et al. Azithromycin protects against Zika" exact="virus infection" post="by upregulating virus-induced type I and III interferon responses."/>
 <result pre="K, Quanquin N, et al. Azithromycin protects against Zika virus" exact="infection" post="by upregulating virus-induced type I and III interferon responses."/>
 <result pre="al. Azithromycin protects against Zika virus infection by upregulating virus-induced" exact="type I" post="and III interferon responses. Antimicrob Agents Chemother. 2019. 10.1128/AAC.00394-19."/>
 <result pre="Microbes Infect2014312e8426038505 18.KawamuraKIchikadoKTakakiMEguchiYAnanKSugaMAdjunctive therapy with azithromycin for moderate and severe" exact="acute" post="respiratory distress syndrome: a retrospective, propensity score-matching analysis of"/>
 <result pre="Infect2014312e8426038505 18.KawamuraKIchikadoKTakakiMEguchiYAnanKSugaMAdjunctive therapy with azithromycin for moderate and severe acute" exact="respiratory" post="distress syndrome: a retrospective, propensity score-matching analysis of prospectively"/>
 <result pre="therapyN Engl J Med2020382191851185232187463 22.MartinezMACompounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob Agents Chemother2020645e00399e0032032152082 23.RuanQYangKWangWJiangLSongJClinical predictors of mortality due"/>
 <result pre="trialCrit Care Med201644227528126584195 26.XuZShiLWangYZhangJHuangLZhangCet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med20208442042232085846 27.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines"/>
 <result pre="Care Med201644227528126584195 26.XuZShiLWangYZhangJHuangLZhangCet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med20208442042232085846 27.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and"/>
 <result pre="Respir Med20208442042232085846 27.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin Exp Immunol200413619510315030519 28.MahallawiWHcollab: Khabour OFZhangQMakhdoumHMSulimanBAMERS-CoV infection in"/>
 <result pre="Med20208442042232085846 27.WongCKLamCWWuAKIpWKLeeNLChanIHet al.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin Exp Immunol200413619510315030519 28.MahallawiWHcollab: Khabour OFZhangQMakhdoumHMSulimanBAMERS-CoV infection in humans"/>
 <result pre="in severe acute respiratory syndromeClin Exp Immunol200413619510315030519 28.MahallawiWHcollab: Khabour OFZhangQMakhdoumHMSulimanBAMERS-CoV" exact="infection" post="in humans is associated with a pro-inflammatory Th1 and"/>
 <result pre="ERK phosphorylation and IL-8 and GM-CSF production by human bronchial" exact="epithelial" post="cellsAm J Physiol Lung Cell Mol Physiol20062901L75L8516085674 33.HuiDYanFChenRHThe effects"/>
 <result pre="Cell Mol Physiol20062901L75L8516085674 33.HuiDYanFChenRHThe effects of azithromycin on patients with" exact="diffuse" post="panbronchiolitis: a retrospective study of 29 casesJ Thorac Dis20135561361724255774"/>
 <result pre="29 casesJ Thorac Dis20135561361724255774 34.KudohSAzumaAYamamotoMIzumiTAndoMImprovement of survival in patients with" exact="diffuse" post="panbronchiolitis treated with low-dose erythromycinAm J Respir Crit Care"/>
 <result pre="Pt 1182918329620913 35.NagaiHShishidoHYonedaRYamaguchiETamuraAKurashimaALong-term low-dose administration of erythromycin to patients with" exact="diffuse" post="panbronchiolitisRespiration.1991583â€&quot;41451491745845 36.WengDWuQChenXQDuYKChenTLiHet al.Azithromycin treats diffuse panbronchiolitis by targeting T"/>
 <result pre="of erythromycin to patients with diffuse panbronchiolitisRespiration.1991583â€&quot;41451491745845 36.WengDWuQChenXQDuYKChenTLiHet al.Azithromycin treats" exact="diffuse" post="panbronchiolitis by targeting T cells via inhibition of mTOR"/>
 <result pre="pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus. bioRxiv. 2020. 10.1101/2020.02.12.945576."/>
 <result pre="GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus. bioRxiv. 2020. 10.1101/2020.02.12.945576. 38.Liao"/>
 <result pre="interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine" exact="pulmonary" post="neutrophiliaInt Immunopharmacol201111442443421195124 40.MeyerMHuauxFGavilanesXvan den BruleSLebecquePLo ReSet al.Azithromycin reduces exaggerated"/>
 <result pre="al.Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in" exact="cystic" post="fibrosisAm J Respir Cell Mol Biol200941559060219244203 41.BanjanacMMunic KosVNujicKVrancicMBelamaricDCrnkovicSet al.Anti-inflammatory"/>
 <result pre="improves macrophage phagocytic function and expression of mannose receptor in" exact="chronic" post="obstructive pulmonary diseaseAm J Respir Crit Care Med2008178213914818420960 44.MurphyBSSundareshanVCoryTJHayesDJrAnsteadMIFeolaDJAzithromycin"/>
 <result pre="phagocytic function and expression of mannose receptor in chronic obstructive" exact="pulmonary" post="diseaseAm J Respir Crit Care Med2008178213914818420960 44.MurphyBSSundareshanVCoryTJHayesDJrAnsteadMIFeolaDJAzithromycin alters macrophage"/>
 <result pre="Sci20095766767819893639 46.LegssyerRHuauxFLebacqJDelosMMarbaixELebecquePet al.Azithromycin reduces spontaneous and induced inflammation in DeltaF508" exact="cystic fibrosis" post="miceRespir Res2006713417064416 47.BMJ Group / Pharmaceutical Press. The British"/>
 <result pre="Preprints. 2020. 10.20944/preprints202003.0302.v1. 49.SerisierDJRisks of population antimicrobial resistance associated with" exact="chronic" post="macrolide use for inflammatory airway diseasesLancet Respir Med20131326227424429132 50.Horby"/>
 <result pre="cause of QT-interval prolongation and torsade de pointes in the" exact="absence of" post="other known precipitating factorsJ Interv Card Electrophysiol200718324324617546486 54.KanohSRubinBKMechanisms of"/>
 <result pre="as immunomodulatory medicationsClin Microbiol Rev201023359061520610825 55.RayWAMurrayKTHallKArbogastPGSteinCMAzithromycin and the risk of" exact="cardiovascular" post="deathN Engl J Med2012366201881189022591294 56.ChengYJNieXYChenXMLinXXTangKZengWTet al.The role of macrolide"/>
 <result pre="J Med2012366201881189022591294 56.ChengYJNieXYChenXMLinXXTangKZengWTet al.The role of macrolide antibiotics in increasing" exact="cardiovascular" post="riskJ Am Coll Cardiol201566202173218426564594 57.Polgreen LA, Riedle BN, Cavanaugh"/>
 <result pre="substantially when adjusting for patient characteristics and comorbidities. J Am" exact="Heart" post="Assoc. 2018;7(9):e008074. 10.1161/JAHA.117.008074. 58.HansenMPScottAMMcCulloughAThorningSAronsonJKBellerEMet al.Adverse events in people taking"/>
</results>
